Fund	Action	Prev Shares	Curr Shares	Change %	Value	Quarter
CITADEL ADVISORS LLC	DOUBLED	38,468	86,326	+124.4%	$69.9K	2025-Q3
UBS Group AG	NEAR_EXIT	20,790	234	-98.9%	$190.00	2025-Q3
NATIONAL BANK OF CANADA /FI/	DOUBLED	174	3,934	+2160.9%	$3.9K	2025-Q2
NATIONAL BANK OF CANADA /FI/	NEAR_EXIT	1,613	174	-89.2%	$150.00	2025-Q1
ROYAL BANK OF CANADA	DOUBLED	672	1,493	+122.2%	$2.0K	2024-Q4
NATIONAL BANK OF CANADA /FI/	TRIM	3,440	1,613	-53.1%	$1.7K	2024-Q4
ROYAL BANK OF CANADA	TRIM	1,226	672	-45.2%	$1.0K	2024-Q3

∅

No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.

8 SEC filing reports analyzed. Sentiment: 1 bullish, 3 bearish, 0 mixed, 4 neutral. Avg impact: 5.1/10.

NEUTRAL 6-K 3/10

XORTX Therapeutics voluntarily delists from the TSX Venture Exchange to reduce costs and regulatory

Jun 12, 2026

BEARISH 6-K, PRESS-RELEASE 6/10

XORTX closed a $5M public offering of 2.66M common shares/pre-funded warrants at $1.88/share, repres

May 19, 2026

BEARISH 424B4 7/10

XORTX Therapeutics priced a $5.0M registered direct offering of 183,577 common shares at $1.88/share

May 15, 2026

BEARISH 6-K 7/10

XORTX Therapeutics announced a $5 million public offering of 2,659,574 common shares (or pre-funded

May 14, 2026

NEUTRAL 6-K 5/10

XORTX Therapeutics announced it has regained compliance with Nasdaq's minimum bid price requirement

Apr 21, 2026

BULLISH 6-K 7/10

XORTX Therapeutics has closed the acquisition of Vectus Biosystems' kidney anti-fibrotic asset, VB4-

Apr 16, 2026

NEUTRAL 6-K 3/10

XORTX Therapeutics held its annual and special meeting of shareholders on March 24, 2026, where all

Mar 27, 2026

NEUTRAL 6-K 3/10

XORTX Therapeutics has delayed the effective date of its planned 1-for-5 share consolidation from Ma

Mar 27, 2026

BEARISH 6/10

XORTX Therapeutics priced a public offering of ~2.66M shares at $1.88/share for $5M gross proceeds,

May 14, 2026

BULLISH 7/10

XORTX Therapeutics has closed its acquisition of Vectus Biosystems' renal anti-fibrotic program, inc

Apr 13, 2026

NEUTRAL 4/10

XORTX Therapeutics has delayed its planned 1-for-5 share consolidation from March 27, 2026, to April

Mar 26, 2026

NEUTRAL 5/10

XORTX Therapeutics is consolidating its shares on a 1:5 basis to maintain compliance with Nasdaq's $

Mar 25, 2026

NEUTRAL 5/10

XORTX Therapeutics announced shareholder approval for a reverse stock split of up to 5:1 to comply w

Mar 24, 2026

Historical analyst distribution: 80% buy across 5 analysts — 1 strong buy, 3 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.

Earnings Estimates & Revisions

Period	EPS Avg	EPS Low	EPS High	EPS Growth	30d Rev.	Up/Down	Rev. Avg	Rev. Growth	Analysts
Current Q	$0.00	$0.00	$0.00	—	—	—	$0.0B	—	—
Next Q	$0.00	$0.00	$0.00	—	—	—	$0.0B	—	—
Current FY 2026-12-31	$0.00	$0.00	$0.00	—	—	—	$0.0B	—	—
Next FY	$0.00	$0.00	$0.00	—	—	—	$0.0B	—	—

Monthly Consensus History

Period	Strong Buy	Buy	Hold	Buy %
Mar 1, 2024	1	3	1	80%
Feb 1, 2024	1	3	1	80%
Jan 1, 2024	1	3	1	80%
Dec 1, 2023	1	3	1	80%

Strong BuyBuyHoldSellStrong Sell

∅

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

∅

No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.

Jun 12, 2026

activist

XORTX Announces Election to Voluntary Delist from the TSX Venture Exchange

CALGARY, Alberta, June 12, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company</st

May 19, 2026

offering

XORTX Announces Closing of US$5 Million Public Offering

CALGARY, Alberta , May 19, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" o

May 14, 2026

activist

XORTX Announces US$5 Million Public Offering

CALGARY, Alberta, May 14, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or

Apr 24, 2026

short_interest

FTD: XRTX — 224,397 shares ($0.6M) failed to deliver

Settlement: 20260424, Price: $2.77, FTD Value: $621,579.69, XORTX THERAPEUTICS INC COM NO

Apr 23, 2026

short_interest

FTD: XRTX — 291,967 shares ($0.8M) failed to deliver

Settlement: 20260423, Price: $2.83, FTD Value: $826,266.61, XORTX THERAPEUTICS INC COM NO

Apr 22, 2026

short_interest

FTD: XRTX — 430,069 shares ($1.2M) failed to deliver

Settlement: 20260422, Price: $2.69, FTD Value: $1,156,885.61, XORTX THERAPEUTICS INC COM NO

Apr 13, 2026

m_and_a

XORTX Announces Closing of Acquisition of Vectus Kidney Anti-fibrotic Asset

• VB4-P5 – novel new chemical entity with potential to address significant unmet

Apr 1, 2026

other

XORTX Confirms Effective Date of Share Consolidation

CALGARY, Alberta, April 01, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company</s

Mar 26, 2026

earnings

XORTX Announces Results of Annual and Special Meeting of Shareholders

CALGARY, Alberta, March 26, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company</s

Mar 26, 2026

activist

XORTX Announces Change of Effective Date of Share Consolidation

CALGARY, Alberta, March 26, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company</s

Mar 25, 2026

activist

XORTX Announces Share Consolidation

CALGARY, Alberta, March 25, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company</s

Mar 24, 2026

activist

XORTX Reports that Shareholders Approved the Share Consolidation at the Annual General Meeting

CALGARY, Alberta, March 24, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company</s

Mar 13, 2026

other

XORTX Reports that Independent Proxy Advisory Firms Recommend XORTX Shareholders Vote “For” the Share Consolidation

CALGARY, Alberta, March 13, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company</s